Quantitative EEG power and synchronization correlate with Alzheimer's disease CSF biomarkers

Smailović, Una; Koenig, Thomas; Kåreholt, Ingemar; Andersson, T.; Kramberger, Milica G.; Winblad, Bengt; Jelić, Vesna

doi:10.1016/j.neurobiolaging.2017.11.005

Cited by 117 publications

(118 citation statements)

References 60 publications

Supporting

Mentioning

105

Contrasting

Unclassified

Order By: Relevance

“…where ␣-synuclein is invariable and amyloid-␤ very common, the frequency of epilepsy is extremely low The qEEG can be considered an indirect marker of neurodegeneration in AD [50]. In our study, the qEEG data were found to be substantially overlapping between AD-EPI and AD-CTR patients while, as a descriptive finding, interictal epileptiform discharges were more likely found in the AD-EPI group.…”

Section: Discussionsupporting

confidence: 43%

Epilepsy in Neurodegenerative Dementias: A Clinical, Epidemiological, and EEG Study

Arnaldi

Donniaquio

Mattioli

et al. 2020

JAD

View full text Add to dashboard Cite

Background: Seizures are common in patients with dementia but precise epidemiologic data of epilepsy in neurodegenerative dementia is lacking. Objective: The first aim of the study was to investigate prevalence and clinical characteristics of epilepsy in a large cohort of patients with neurodegenerative dementias. Subsequently, we explored clinical, neuropsychological, and quantitative electroencephalogram (qEEG) data of Alzheimer's disease (AD) patients with epilepsy (AD-EPI) as compared to AD patients without epilepsy (AD-CTR). Methods: We retrospectively evaluated consecutive patients with a diagnosis of a neurodegenerative dementia and a clinically diagnosed epilepsy that required antiepileptic drugs (AED). All patients underwent baseline comprehensive neuropsychological assessment. A follow-up of at least one year was requested to confirm the dementia diagnosis. In AD patients, qEEG power band analysis was performed. AD-CTR and AD-EPI patients were matched for age, Mini-Mental State Examination score, and gender. Results: Thirty-eight out of 2,054 neurodegenerative dementia patients had epilepsy requiring AED. The prevalence of epilepsy was 1.82% for AD, 1.28% for the behavioral variant of frontotemporal dementia (bvFTD), 2.47% for dementia with Lewy bodies (DLB), and 12% for primary progressive aphasia. Epilepsy were more drug-responsive in AD than in non-AD dementias. Finally, no significant differences were found in neuropsychological and qEEG data between AD-EPI and AD-CTR patients. Conclusion: In our cohort, AD, FTD, and DLB dementias have similar prevalence of epilepsy, even if AD patients were more responsive to AED. Moreover, AD-EPI patients did not have significant clinical, neuropsychological qEEG differences compared with AD-CTR patients.

show abstract

Section: Discussionsupporting

confidence: 43%

Epilepsy in Neurodegenerative Dementias: A Clinical, Epidemiological, and EEG Study

Arnaldi

Donniaquio

Mattioli

et al. 2020

JAD

View full text Add to dashboard Cite

show abstract

“…Overall, quantitative EEG analysis provides the most direct and dynamic clinical representation of neuronal and synaptic function in AD patients; however, while it is sensitive to changes in neuronal circuit responses resulting from synaptic dysfunction, it cannot discriminate between the exact mechanisms of action underlying synaptic dys/function. Alterations in quantitative measures derived from EEG data in patients with AD have been widely described and have been shown to be sensitive to disease progression [134,138,139] and to correlate with CSF biomarkers of AD [140]. Furthermore, EEG is non-invasive, robust, efficacious, and widely available in hospitals.…”

Section: Biomarkers Of Synapse Damage or Lossmentioning

confidence: 99%

The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease

et al. 2020

View full text Add to dashboard Cite

Background: Synapse damage and loss are fundamental to the pathophysiology of Alzheimer's disease (AD) and lead to reduced cognitive function. The goal of this review is to address the challenges of forging new clinical development approaches for AD therapeutics that can demonstrate reduction of synapse damage or loss. The key points of this review include the following: Synapse loss is a downstream effect of amyloidosis, tauopathy, inflammation, and other mechanisms occurring in AD. Synapse loss correlates most strongly with cognitive decline in AD because synaptic function underlies cognitive performance. Compounds that halt or reduce synapse damage or loss have a strong rationale as treatments of AD. Biomarkers that measure synapse degeneration or loss in patients will facilitate clinical development of such drugs. The ability of methods to sensitively measure synapse density in the brain of a living patient through synaptic vesicle glycoprotein 2A (SV2A) positron emission tomography (PET) imaging, concentrations of synaptic proteins (e.g., neurogranin or synaptotagmin) in the cerebrospinal fluid (CSF), or functional imaging techniques such as quantitative electroencephalography (qEEG) provides a compelling case to use these types of measurements as biomarkers that quantify synapse damage or loss in clinical trials in AD. Conclusion: A number of emerging biomarkers are able to measure synapse injury and loss in the brain and may correlate with cognitive function in AD. These biomarkers hold promise both for use in diagnostics and in the measurement of therapeutic successes.

show abstract

“…Another possible explanation would concur with the results obtained in other neurodegenerative diseases such as Alzheimer's; Lopez et al [65] found increased functional brain activity in anterior circuits using magnetoencephalography in mild cognitive impairment (an early condition in dementia). In [66], it was suggested that this hyperactivity may be one of the earliest dysfunctions of the pathophysiological process of neurodegeneration and would subsequently decline as dementia develops [67].…”

Section: Discussionmentioning

confidence: 99%

Empirical Mode Decomposition-Based Filter Applied to Multifocal Electroretinograms in Multiple Sclerosis Diagnosis

Santiago

Castillo

García‐Martín

et al. 2019

Sensors

View full text Add to dashboard Cite

As multiple sclerosis (MS) usually affects the visual pathway, visual electrophysiological tests can be used to diagnose it. The objective of this paper is to research methods for processing multifocal electroretinogram (mfERG) recordings to improve the capacity to diagnose MS. MfERG recordings from 15 early-stage MS patients without a history of optic neuritis and from 6 control subjects were examined. A normative database was built from the control subject signals. The mfERG recordings were filtered using empirical mode decomposition (EMD). The correlation with the signals in a normative database was used as the classification feature. Using EMD-based filtering and performance correlation, the mean area under the curve (AUC) value was 0.90. The greatest discriminant capacity was obtained in ring 4 and in the inferior nasal quadrant (AUC values of 0.96 and 0.94, respectively). Our results suggest that the combination of filtering mfERG recordings using EMD and calculating the correlation with a normative database would make mfERG waveform analysis applicable to assessment of multiple sclerosis in early-stage patients. Author Contributions: Conceptualization, E.G.-M., M.J.R., E.M.S.M., and L.B.; methodology, L.d.S., M.O.d.C., C.C., J.M.M., A.L., and B.C.; software, L.d.S., M.O.d.C., C.C., J.M.M., and A.L.; validation, L.d.S., M.O.d.C., C.C., J.M.M., and A.L.; formal Analysis, M.O.d.C. and J.M.M.; investigation, E.G.-M., M.J.R., E.M.S.M., and L.B.; resources, L.B. and E.G.-M.; data Curation, L.d.S., M.O.d.C., C.C., J.M.M., A.L., and B.C.; writing-original draft preparation, L.B., E.G.-M., and M.J.R.; writing-review and editing, L.B., E.G.-M., and M.J.R.; visualization, L.B. and E.G.-M.; supervision, L.B. and E.G.-M.; project administration, L.B. and E.G.-M.; funding acquisition, L.B. and E.G.-M. All authors have read and agreed to the published version of the manuscript.

show abstract

Quantitative EEG power and synchronization correlate with Alzheimer's disease CSF biomarkers

Cited by 117 publications

References 60 publications

Epilepsy in Neurodegenerative Dementias: A Clinical, Epidemiological, and EEG Study

Epilepsy in Neurodegenerative Dementias: A Clinical, Epidemiological, and EEG Study

The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease

Empirical Mode Decomposition-Based Filter Applied to Multifocal Electroretinograms in Multiple Sclerosis Diagnosis

Contact Info

Product

Resources

About